[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Baderca F, Lighezan R, Dema A, Alexa A, Raica M: Immunohistochemical expression of VEGF in normal human renal parenchyma. Rom J Morphol Embryol; 2006;47(4):315-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of VEGF in normal human renal parenchyma.
  • In the normal kidney, VEGF is constitutively expressed in podocytes and tubular epithelial cells of the renal cortex and medulla.
  • The aim of this study was to determine distribution of VEGF in normal renal parenchyma using immunohistochemical methods.
  • The study was retrospective, using normal kidneys samples taken from 28 patients with nephroureterectomy for different types of renal cell carcinomas.
  • All cases presented an intense immunoreaction in the cells lining the nephron tubular system, the higher immunoreaction intensity in the collecting and distal tubules, but weak or moderate in the proximal tubules.
  • The immunoreaction was absent in most cells of the renal corpuscle.
  • The cells lining the same tubule presented some variation of intensity, with large polygonal epithelial cells, bulging in the tubular lumen showing an intense cytoplasmic immunoreaction for VEGF.
  • In the renal parenchyma adjacent to the tumor, we observed the same pattern of positive reaction distribution as in the nephron's epithelial tubular cells situated far from the tumor.
  • Adjacent to the tumor proliferation front and in those cases with massive invasive features, we observed a partial depletion of VEGF in distal tubules, while the majority of collecting ducts remained intense positive.
  • The VEGF immunostaining was significantly higher in the renal cortex than in the outer and respectively the inner medulla.
  • [MeSH-major] Kidney / cytology. Kidney / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Humans. Immunohistochemistry. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392976.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


2. Azarpira N, Torabineghad S, Rakei M: Brain tumor as an unusual presentation of posttransplant lymphoproliferative disorder. Exp Clin Transplant; 2009 Mar;7(1):58-61
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor as an unusual presentation of posttransplant lymphoproliferative disorder.
  • OBJECTIVES: Posttransplant lymphoproliferative disorder following solid organ transplant is a lifethreatening form of posttransplant malignancy.
  • Its occurrence is typically associated with Epstein-Barr virus and profound immunosuppressive therapy.
  • We describe a case of posttransplant lymphoproliferative disorder in the brain parenchyma, 4 years after renal transplant.
  • CASE REPORT: A 23-year-old man was evaluated for generalized headache 4 years after receiving a deceased donor renal transplant.
  • A tumor in the right occipitoparietal lobe was detected by magnetic resonance imaging and excised.
  • Immunohistochemical testing of the tumor revealed B-cell marker and Epstein-Barr virus.
  • After surgery, the dosage of immunosuppressive drugs was reduced, and the patient was treated with chemotherapy and radiotherapy.
  • Our patient is well after treatment.
  • CONCLUSIONS: Reduction in immunosuppressive therapy is an important component of treatment for Epstein-Barr virus-positive posttransplant lymphoproliferative disorder and may lead to remission in early disease.
  • If reduced immunosuppression fails to control early disease, cytotoxic chemotherapy, surgery and radiotherapy, antiviral therapies, and cell-based therapies are other options for treatment.
  • [MeSH-major] Brain Neoplasms / virology. Epstein-Barr Virus Infections / complications. Immunosuppressive Agents / adverse effects. Kidney Transplantation / adverse effects. Lymphoproliferative Disorders / virology. Occipital Lobe / virology. Parietal Lobe / virology
  • [MeSH-minor] Chemotherapy, Adjuvant. Cranial Irradiation. Craniotomy. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Radiotherapy, Adjuvant. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19364315.001).
  • [ISSN] 1304-0855
  • [Journal-full-title] Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
  • [ISO-abbreviation] Exp Clin Transplant
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


3. Ghanem MA, van Steenbrugge GJ, Sudaryo MK, Mathoera RB, Nijman JM, van der Kwast TH: Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol; 2003 Feb;56(2):107-13
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To investigate the prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor Flt-1 in nephroblastoma and whether tumour microvessel density (MVD) immunoreactivity, determined by the CD31 antigen, is related to the expression of VEGF and Flt-1.
  • Patients were treated preoperatively with chemotherapy and had a mean follow up of 5.7 years.
  • RESULTS: In general, VEGF and Flt-1 were expressed in normal kidney parenchyma and to a variable extent in the three main components of Wilms's tumour, namely: the blastemal, epithelial, and stromal cells.
  • In tumour tissue, 52% and 47% of blastemal cells were positive for VEGF and Flt-1, respectively.
  • Univariate analysis showed that the expression of VEGF and Flt-1 in blastemal cells was indicative of clinical progression and tumour specific survival.
  • CONCLUSIONS: These results indicate that VEGF and Flt-1 protein expression are closely related to MVD and seem to be an important predictor for poor prognosis in treated patients with Wilms's tumour.
  • Therefore, the expression of these molecules in primary Wilms's tumour may be useful in identifying those patients at high risk of tumour recurrence and in guiding antiangiogenic treatment.
  • [MeSH-major] Kidney Neoplasms / metabolism. Neoplasm Proteins / metabolism. Neovascularization, Pathologic / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Wilms Tumor / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1995 Jul;147(1):33-41 [7541612.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1029-39 [7538264.001]
  • [Cites] J Pathol. 1995 Sep;177(1):57-63 [7472781.001]
  • [Cites] Adv Cancer Res. 1995;67:281-316 [8571818.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):858-63 [8608475.001]
  • [Cites] J Neurosci. 1996 Oct 1;16(19):6089-99 [8815891.001]
  • [Cites] Gynecol Oncol. 1996 Nov;63(2):204-9 [8910628.001]
  • [Cites] J Natl Cancer Inst. 1997 Jan 15;89(2):139-47 [8998183.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):826-32 [9053510.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):98-106 [9210714.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2811-4 [9252720.001]
  • [Cites] Lab Invest. 1997 Dec;77(6):607-14 [9426398.001]
  • [Cites] J Gastroenterol. 1998 Jun;33(3):376-82 [9658317.001]
  • [Cites] Br J Cancer. 1998 Nov;78(10):1379-84 [9823983.001]
  • [Cites] J Clin Pathol. 1998 Oct;51(10):771-5 [10023341.001]
  • [Cites] J Pediatr Surg. 1999 May;34(5):743-7; discussion 747-8 [10359175.001]
  • [Cites] Oncol Rep. 1999 Sep-Oct;6(5):959-64 [10425286.001]
  • [Cites] Pediatr Dev Pathol. 1998 May-Jun;1(3):243-8 [10463285.001]
  • [Cites] Science. 1983 Feb 25;219(4587):983-5 [6823562.001]
  • [Cites] Oncogene. 1990 Apr;5(4):519-24 [2158038.001]
  • [Cites] Arch Dis Child. 1990 Sep;65(9):968-70 [2171439.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Dec 16;181(2):902-6 [1755866.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1335-43 [10604730.001]
  • [Cites] J Pediatr Surg. 2000 Jan;35(1):30-2; discussion 32-3 [10646769.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):572-7 [10690541.001]
  • [Cites] J Urol. 2001 Jun;165(6 Pt 2):2274-9 [11371962.001]
  • [Cites] Science. 1987 Jan 23;235(4787):442-7 [2432664.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Science. 1992 Feb 21;255(5047):989-91 [1312256.001]
  • [Cites] Development. 1992 Feb;114(2):521-32 [1592003.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Feb 15;190(3):702-8 [8439321.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4727-35 [8402650.001]
  • [Cites] Int J Cancer. 1993 Nov 11;55(5):739-44 [8244569.001]
  • [Cites] Cancer Metastasis Rev. 1993 Sep;12(3-4):303-24 [8281615.001]
  • [Cites] Ann Plast Surg. 1994 Jun;32(6):588-94 [7521149.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):353-6 [7535719.001]
  • [Cites] Int J Cancer. 1995 Mar 29;61(1):148-52 [7535752.001]
  • [Cites] J Biol Chem. 1995 Apr 28;270(17):9709-16 [7730348.001]
  • [Cites] Jpn J Clin Oncol. 1995 Apr;25(2):25-31 [7745819.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):193-204 [8534867.001]
  • (PMID = 12560388.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Neoplasm Proteins; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  • [Other-IDs] NLM/ PMC1769871
  •  go-up   go-down


Advertisement
4. Takase Y, Kohno M, Kobayashi T, Tokunaga S, Imamura Y: [Bellini duct carcinoma: a case report]. Hinyokika Kiyo; 2004 Jun;50(6):425-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 53-year-old man was admitted to our hospital for the extensive examination and treatment of suspicioun of right renal pelvic tumor.
  • Retrograde pyelography (RP), computed tomography (CT) and magnetic resonance imaging (MRI) showed a space-occupying lesion, about 2 cm in diameter, spread from the renal parenchyma to the renal pelvis.
  • The gross examination revealed a white tumor in the upper pole, protruding into the renal pelvis with hemorrhagic necrosis.
  • Histological examination showed Bellini duct carcinoma of the papillary type.
  • He received adjuvant combination chemotherapy with M-VAC (Methotrexate, vinblastine, doxorubicin, cisplatin).
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Kidney Tubules, Collecting
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15293743.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 8
  •  go-up   go-down


5. Günther P, Tröger J, Graf N, Waag KL, Schenk JP: MR volumetric analysis of the course of nephroblastomatosis under chemotherapy in childhood. Pediatr Radiol; 2004 Aug;34(8):660-4
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR volumetric analysis of the course of nephroblastomatosis under chemotherapy in childhood.
  • Nephroblastomatosis is a paediatric renal disease that may undergo malignant transformation.
  • When neoadjuvant chemotherapy is indicated for nephroblastomatosis or bilateral Wilms' tumours, exact volumetric analysis using high-speed data processing and visualization may aid in determining tumour response.
  • Exact volume determination of foci of nephroblastomatosis was performed by automatic and manual segmentation, and the relation to normal renal parenchyma was determined over a 12-month period.
  • At the first visit, 80% (460/547 ml) of the extremely enlarged right kidney was due to nephroblastomatosis.
  • Total tumour volume within the right kidney decreased to 74 ml under chemotherapy.
  • Volume analysis of the two emerging right-sided masses after treatment correctly suggested Wilms' tumour.
  • Three-dimensional rendering of the growing masses aided the surgeon in nephron-sparing surgery during tumour resection.
  • [MeSH-major] Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Magnetic Resonance Imaging. Wilms Tumor / drug therapy. Wilms Tumor / pathology
  • [MeSH-minor] Child, Preschool. Female. Humans. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1992 Jan;182(1):1-5 [1309213.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1903-8 [12168891.001]
  • [Cites] Thyroid. 2002 Aug;12 (8):713-7 [12225640.001]
  • [Cites] Pediatr Pathol. 1990;10(1-2):1-36 [2156243.001]
  • [Cites] Lancet. 1975 Sep 13;2(7933):482-4 [51289.001]
  • [Cites] Radiographics. 1998 Jul-Aug;18(4):947-68 [9672980.001]
  • [Cites] Med Pediatr Oncol. 2000 Oct;35(4):429-32; discussion 433 [11025476.001]
  • [Cites] Med Pediatr Oncol. 1993;21(3):158-68 [8383276.001]
  • [Cites] Invest Radiol. 1999 Feb;34(2):143-50 [9951794.001]
  • [Cites] Rofo. 2001 Nov;173(11):991-6 [11704908.001]
  • [Cites] Radiology. 1993 Aug;188(2):517-21 [8392214.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(5):401-4 [12440811.001]
  • [Cites] Radiology. 2002 Sep;224(3):683-94 [12202700.001]
  • [Cites] Pediatr Radiol. 1998 Jun;28(6):435-43 [9634458.001]
  • [Cites] Cancer Invest. 1997;15(2):153-62 [9095211.001]
  • [Cites] J Pediatr Surg. 1990 Sep;25(9):933-7; discussion 937-8 [2170616.001]
  • (PMID = 15103425.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Cho KS, Cho NH, Park SY, Cho SY, Choi YD, Chung BH, Yang SC, Hong SJ: Prognostic impact of peripelvic fat invasion in pT3 renal pelvic transitional cell carcinoma. J Korean Med Sci; 2008 Jun;23(3):434-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of peripelvic fat invasion in pT3 renal pelvic transitional cell carcinoma.
  • Renal pelvic transitional cell carcinoma (TCC), which invades beyond muscularis into peripelvic fat or the renal parenchyma, is diagnosed as stage pT3 despite its structural complexity.
  • We evaluated the prognostic impact of peripelvic fat invasion in pT3 renal pelvic TCC.
  • Between 1986 and 2004, the medical records on 128 patients who were surgically treated for renal pelvic TCC were retrospectively reviewed.
  • On univariate analysis, sex, age, concomitant bladder tumors, concomitant ureter tumors, lymphadenectomy, adjuvant chemotherapy, tumor grade, multiplicity, renal parenchymal invasion, and carcinoma in situ did not influence the disease-specific survival (p>0.05).
  • In conclusion, peripelvic fat invasion is a strong prognostic factor in pT3 renal pelvic TCC.
  • Thus, systemic adjuvant therapy should be considered in the presence of peripelvic fat invasion, even if the lymph nodes are not involved.
  • [MeSH-major] Adipose Tissue / pathology. Carcinoma, Transitional Cell / pathology. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Jun 15;94(12):3150-6 [12115347.001]
  • [Cites] J Urol. 1946 Apr;55:366-72 [21020382.001]
  • [Cites] JAMA. 1971 Nov 8;218(6):845-54 [4939530.001]
  • [Cites] J Urol. 1978 May;119(5):594-7 [660726.001]
  • [Cites] J Urol. 1980 May;123(5):629-31 [7420546.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):2016-20 [3167813.001]
  • [Cites] Cancer. 1990 Nov 1;66(9):1919-23 [2224787.001]
  • [Cites] J Urol. 1991 Jun;145(6):1159-63 [2033684.001]
  • [Cites] Cancer. 1992 Apr 1;69(7):1773-5 [1551062.001]
  • [Cites] Urology. 1995 Dec;46(6):796-800 [7502418.001]
  • [Cites] CA Cancer J Clin. 1998 Jan-Feb;48(1):6-29 [9449931.001]
  • [Cites] Urology. 1998 Oct;52(4):594-601 [9763077.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1435-48 [9850170.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):738-43 [10505034.001]
  • [Cites] Am J Surg Pathol. 2004 Dec;28(12):1545-52 [15577672.001]
  • [Cites] J Urol. 2005 Dec;174(6):2120-3; discussion 2124 [16280740.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):621-5 [14713773.001]
  • (PMID = 18583879.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2526530
  •  go-up   go-down


7. Morales Concepción JC, Cordiés Jackson E, Sandin Hernández N, Renó Céspedes J, Moreno Díaz ME: [Metachronous bilateral Wilms' tumor]. Arch Esp Urol; 2000 Apr;53(3):245-7
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metachronous bilateral Wilms' tumor].
  • [Transliterated title] Tumor de Wilms bilateral metacrónico.
  • OBJECTIVE: To report on a female patient with metachronous bilateral Wilms' tumor with a long survival.
  • METHODS: An 11-year-old girl underwent total nephrectomy when she was 4 years old for Wilms' tumor of the right kidney.
  • She received cobalt therapy and chemotherapy, and the evolution was good for three years, at which time a control US scan detected a tumor in the left kidney that was diagnosed as Wilms' tumor.
  • She underwent a partial nephrectomy at the Hospital Pediátrico de Centro Habana (Cuba) and received chemotherapy.
  • RESULTS/CONCLUSION: A recent US scan and a descending pyelogram showed completely normal findings and growth of the remaining renal parenchyma.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Wilms Tumor / diagnosis

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10851730.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] SPAIN
  •  go-up   go-down


8. Si J, Ge Y, Zhuang S, Gong R: Inhibiting nonmuscle myosin II impedes inflammatory infiltration and ameliorates progressive renal disease. Lab Invest; 2010 Mar;90(3):448-58

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibiting nonmuscle myosin II impedes inflammatory infiltration and ameliorates progressive renal disease.
  • In vivo, in a rat model of acute inflammation induced by tumor necrosis factor, blebbistatin obliterated renal sequestration of circulating fluorescence-labeled macrophages in a dose-dependent fashion.
  • Moreover, in rats with progressive obstructive nephropathy, blebbistatin treatment exhibited a remarkable renoprotective effect, as evidenced by normalized kidney weight, improved gross morphology, and diminished histologic injury in the tubulointerstitium.
  • This beneficial effect was associated with significant amelioration of renal inflammation, consistent with a primary anti-inflammatory action by blebbistatin.
  • In addition, in rats with established obstructive nephropathy, blebbistatin pretreated macrophages showed obliterated recruitment into the inflamed renal parenchyma, denoting that blebbistatin directly impedes inflammatory infiltration by immunocytes.
  • [MeSH-major] Heterocyclic Compounds with 4 or More Rings / pharmacology. Nephritis / drug therapy. Nonmuscle Myosin Type IIA / antagonists & inhibitors
  • [MeSH-minor] Actins / metabolism. Animals. Cell Movement / drug effects. Humans. Jurkat Cells. Kidney / pathology. Macrophages / drug effects. Male. Rats. Rats, Sprague-Dawley. Tumor Necrosis Factor-alpha. Ureteral Obstruction / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065948.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Heterocyclic Compounds with 4 or More Rings; 0 / Tumor Necrosis Factor-alpha; 0 / blebbistatin; EC 3.6.1.- / Nonmuscle Myosin Type IIA
  •  go-up   go-down


9. Acosta D, Martínez-Ibáñez V, Lloret J, Abad P, al-Kassab H, Boix-Ochoa J: [Partial nephrectomy in unilateral Wilms tumor. New draft for a protocol of the SIOP]. Cir Pediatr; 2001 Oct;14(4):139-40
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Partial nephrectomy in unilateral Wilms tumor. New draft for a protocol of the SIOP].
  • [Transliterated title] Nefrectomía parcial en el tumor de Wilms unilateral. Nuevo borrador de protocolo de la SIOP.
  • Unilateral Wilms' tumor has been treated according to 9301 SIOP protocol, with good results.
  • From 1993 to 1999, 11 patients with unilateral Wilms' tumor were treated in our center; in 6 cases preop chemotherapy was done, in the other 5 cases pre and postoperative chemotherapy were used.
  • Nine of the 11 patients could be included in the pre protocol this was due to a thrombosis of the vena cava in one case, and in the other the middle renal in area was widely affected.
  • Wilms' tumor has a good prognosis with the actual protocol, SIOP.
  • New pre protocol could give a better quality of life due to the amount of functional renal parenchyma, without decreasing the actual high cure rate.
  • [MeSH-major] Clinical Protocols. Kidney Neoplasms / surgery. Nephrectomy / methods. Wilms Tumor / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12601960.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


10. Sato H, Hori K, Sugiyama K, Tanda S, Sato Y: [Tumor microcirculation and selective enhancement of drug delivery--clinical applications based on pathophysiological experiments]. Gan To Kagaku Ryoho; 2000 Jul;27(8):1191-200
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tumor microcirculation and selective enhancement of drug delivery--clinical applications based on pathophysiological experiments].
  • Tumor tissue is composed of cancer cells (parenchyma) and tumor vessels (interstitium).
  • This would be a certain cause of insufficient drug delivery to tumor tissues.
  • Among the experimental evidence using Yoshida Sarcoma and Ascites Hepatomas, functional differences in microcirculation between tumor and normal tissues were found by Suzuki et al. (1977).
  • Under hypertensive state induced by the continuous infusion of angiotensin II, tumor blood flow increased remarkably, while there was no change or decrease in blood flow in normal tissues such as the brain, bone marrow, liver and kidney.
  • Augmentation of the anti-tumor effects of angiotensin II-induced hypertension chemotherapy (IHC) for advanced gastric carcinoma was revealed in two randomized controlled trials (RCT-1 & 2) of collaborative study groups in Japan.
  • It is very important for exact evaluation after chemotherapy to understand or estimate the pathohistological changes in the tumor and its degenerated or repaired tissues, which present various clinical images.
  • IHC with smaller DI could lead to a reduction in the accumulation of toxicities of anti-cancer drugs in the host.
  • In conclusion, IHC might be applied to all kinds of tumors to enhance the chemotherapeutic effects through selective increase of drug delivery to tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Delivery Systems / methods. Sarcoma, Yoshida / blood supply. Sarcoma, Yoshida / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Animals. Blood Pressure / drug effects. Doxorubicin / administration & dosage. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Microcirculation. Mitomycin / administration & dosage. Rats

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10945016.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil; FAM protocol
  • [Number-of-references] 77
  •  go-up   go-down


11. Neville H, Ritchey ML, Shamberger RC, Haase G, Perlman S, Yoshioka T: The occurrence of Wilms tumor in horseshoe kidneys: a report from the National Wilms Tumor Study Group (NWTSG). J Pediatr Surg; 2002 Aug;37(8):1134-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The occurrence of Wilms tumor in horseshoe kidneys: a report from the National Wilms Tumor Study Group (NWTSG).
  • BACKGROUND/PURPOSE: An increased incidence of Wilms tumor has been noted in patients with a horseshoe kidney.
  • These represent a difficult diagnostic and therapeutic challenge.
  • The charts of all National Wilms Tumor Study Group (NWTSG) patients with Wilms tumor occurring in a horseshoe kidney were reviewed.
  • Forty-one patients were found to have a Wilms tumor arising in a horseshoe kidney for an incidence of 0.48%.
  • RESULTS: Horseshoe kidney was not recognized preoperatively in 13 patients, 10 of whom were evaluated with computed tomography (CT).
  • Four of the 10 also had renal ultrasonography and one an intravenous pyelogram (IVP).
  • Fifteen children were treated with preoperative chemotherapy after initial biopsy of the tumor.
  • The mean total remaining renal parenchyma after all operations (excluding treatment of relapses) was approximately 75%.
  • Two patients had transient renal failure.
  • CONCLUSIONS: The diagnosis of horseshoe kidney often was missed on preoperative imaging.
  • Although 37% of patients with Wilms tumor arising in a horseshoe kidney were judged inoperable at initial exploration, all were amenable to resection after chemotherapy.
  • [MeSH-major] Congenital Abnormalities / epidemiology. Kidney / abnormalities. Kidney Neoplasms / epidemiology. Wilms Tumor / epidemiology
  • [MeSH-minor] Biopsy. Chemotherapy, Adjuvant. Child, Preschool. Comorbidity. Female. Humans. Incidence. Male. Neoplasm Staging. Nephrectomy. Premedication. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Birth Defects.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12149688.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Cozzi DA, Schiavetti A, Morini F, Castello MA, Cozzi F: Nephron-sparing surgery for unilateral primary renal tumor in children. J Pediatr Surg; 2001 Feb;36(2):362-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephron-sparing surgery for unilateral primary renal tumor in children.
  • PURPOSE: Definition of the role of nephron-sparing surgery (NSS) in the treatment of children with primary unilateral renal tumor (URT).
  • Criteria for selection of patients eligible for NSS were at least 50% of affected kidney preservable and stage I at surgery (frozen section biopsies from regional lymph nodes, perirenal fat, and surrounding renal parenchyma).
  • Preoperative 2-drug chemotherapy was given to all patients more than 6 months of age.
  • Between 1992 and 1995, 3-drug chemotherapy was used after NSS.
  • Thereafter, following NSS, 2-drug chemotherapy was given if no microscopic residual disease was found on final histologic examination.
  • Seven children had standard histology nephroblastoma, 1 highly differentiated epithelial type nephroblastoma, 1 oncocytoma, and 1 cystic nephroma.
  • All children are alive and disease free with good functioning of the affected kidney after NSS, at a mean follow-up of 40.7 months (range, 2 to 100 months).
  • CONCLUSION: NSS should be considered in selected children with URT, especially in patients with increased risk for metachronous tumor or renal disease, and in patients with benign or low-grade malignant URT.
  • [MeSH-major] Kidney Neoplasms / surgery. Nephrectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11172435.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Cozzi F, Schiavetti A, Cozzi DA, Morini F, Uccini S, Pierani P, Martino A: Conservative management of hyperplastic and multicentric nephroblastomatosis. J Urol; 2004 Sep;172(3):1066-9; discussion 1069-70
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The treatment of hyperplastic nephroblastomatosis remains controversial.
  • We report the advantages of conservative management of hyperplastic and multicentric nephroblastomatosis associated with unilateral Wilms tumor (WT).
  • Children with multiple solid renal masses on imaging were treated with 2-drug chemotherapy until disappearance of the lesions.
  • Stabilization or progression of the lesions despite chemotherapy, as well as heterogeneity of the lesions on imaging, prompted nephron sparing surgery (NSS).
  • RESULTS: Three female infants (12, 13 and 20 months old, respectively) presented with multiple solid renal tumors at imaging.
  • Despite chemotherapy, small and unilateral WT developed in 2 cases of hyperplastic nephroblastomatosis, which was excised.
  • The third infant, who presented with unilateral multicentric WT and unilateral hyperplastic nephroblastomatosis nodules, was successfully treated with preoperative chemotherapy and enucleation of 5 tumors.
  • Subsequently, nephrectomy was performed at another institution because the abnormal kidney outline due to NSS was misinterpreted as a recurrence of WT.
  • In some infants with multiple solid renal masses on imaging chemotherapy and for developing WT NSS may safely allow maximum sparing of the parenchyma of both kidneys.
  • [MeSH-major] Kidney Neoplasms / therapy. Neoplasms, Multiple Primary / therapy. Wilms Tumor / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Hyperplasia. Infant. Nephrectomy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15311039.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Buemi M, Fazio MR, Bolignano D, Coppolino G, Donato V, Lacquaniti A, Mondello S, Buemi A, Allegra A: Renal complications in oncohematologic patients. J Investig Med; 2009 Dec;57(8):892-901
MedlinePlus Health Information. consumer health - Kidney Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal complications in oncohematologic patients.
  • The aim of the present paper was to review recent developments in the management of patients with acute kidney injury or chronic kidney disease occurring secondary to either cancer itself or its therapy, with a focus on infiltration of the renal parenchyma, myeloma, tumor lysis syndrome, glomerular disease, thrombotic microangiopathy, chemotherapy-associated thrombotic microangiopathy, biphosphonate-induced renal diseases, acute kidney injury, and chronic kidney disease after hematopoietic cell transplantation.
  • Further studies are awaited because a better knowledge of renal complications, which frequently occur in patients with oncohematologic diseases, would be conducive to making an early diagnosis and providing prompt therapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Hematologic Diseases / complications. Kidney Diseases / chemically induced. Kidney Diseases / etiology. Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952895.001).
  • [ISSN] 1708-8267
  • [Journal-full-title] Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  • [ISO-abbreviation] J. Investig. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 133
  •  go-up   go-down


15. Basile C, Montanaro A: [An exceptionally severe hyperuricemia in acute renal failure caused by spontaneous tumor lysis syndrome (TLS)]. G Ital Nefrol; 2003 Sep-Oct;20(5):525-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An exceptionally severe hyperuricemia in acute renal failure caused by spontaneous tumor lysis syndrome (TLS)].
  • Acute tumor lysis syndrome (TLS) is a catastrophic complication of the treatment of certain neoplastic disorders.
  • It most commonly occurs in association with hematologic malignancies and manifests a few hours to a few days after initiation of specific chemotherapy.
  • Acute spontaneous TLS has been described in leukemia and lymphoma and in some patients with solid tumors prior to institution of therapy.
  • The findings that may be seen in acute TLS include hyperphosphatemia, hypocalcemia, hyperuricemia, hyperkalemia, and acute oliguric or anuric renal failure due to uric acid precipitation within the tubules (acute uric acid nephropathy) and to calcium phosphate deposition in the renal parenchyma and vessels.
  • The patient underwent acute oliguric renal failure soon after right colectomy.
  • The renal function recovered in such a rapid way that no dialysis treatment was required.
  • The administration of a large volume of saline was able to ensure a complete recovery of renal function.
  • Therefore, hydration with saline remains the keystone in the prevention and treatment of acute TLS.
  • [MeSH-major] Acute Kidney Injury / etiology. Hyperuricemia / etiology. Tumor Lysis Syndrome / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14634969.001).
  • [ISSN] 0393-5590
  • [Journal-full-title] Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
  • [ISO-abbreviation] G Ital Nefrol
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Noguera-Irizarry WG, Hibshoosh H, Papadopoulos KP: Renal medullary carcinoma: case report and review of the literature. Am J Clin Oncol; 2003 Oct;26(5):489-92
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal medullary carcinoma: case report and review of the literature.
  • Renal medullary carcinoma is a recently recognized epithelial malignant tumor arising in the renal parenchyma.
  • The tumor is almost exclusive to young black patients with the sickle cell trait.
  • An Hispanic woman with renal medullary carcinoma who initially responded to chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin and survived for 12 months is presented.
  • The clinical, histologic, and radiologic features of this tumor are described, and chemotherapeutic regimens used in this disease are detailed.
  • Treatment modalities have proved largely unsuccessful in the setting of advanced disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Medullary / drug therapy. Kidney Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14528077.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  • [Number-of-references] 24
  •  go-up   go-down


17. Vicens J, Iotti A, Lombardi MG, Iotti R, de Davila MT: Diffuse hyperplastic perilobar nephroblastomatosis. Pediatr Dev Pathol; 2009 May-Jun;12(3):237-8
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography scan showed a homogeneous, isointense enlarged left kidney.
  • A fine needle aspiration cytology was reported as Wilms tumor.
  • After chemotherapy, the left kidney was excised.
  • Nephrectomy specimen presented a thick cortical rim of hyperplastic nephrogenic tissue, well delineated from preserved renal parenchyma without pseudocapsule.
  • Nephroblastomatosis is a rare condition affecting renal parenchyma.
  • Diagnosis is based on imaging studies, such as ultrasound, computed tomography scan, and magnetic resonance imaging.
  • Therapeutic management is controversial.
  • Chemotherapy is used preoperatively, and surgical excision may be an alternative for refractory cases.
  • [MeSH-major] Kidney / pathology. Kidney Neoplasms / pathology. Precancerous Conditions / pathology. Wilms Tumor / pathology
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Disease Progression. Humans. Hyperplasia. Infant. Male. Nephrectomy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18597570.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. De Vriese AS, Bourgeois M: Pharmacologic treatment of acute renal failure in sepsis. Curr Opin Crit Care; 2003 Dec;9(6):474-80
MedlinePlus Health Information. consumer health - Sepsis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacologic treatment of acute renal failure in sepsis.
  • The pathophysiology of acute renal failure in sepsis is complex and includes intrarenal vasoconstriction, infiltration of inflammatory cells in the renal parenchyma, intraglomerular thrombosis, and obstruction of tubuli with necrotic cells and debris.
  • Attempts to interfere pharmacologically with these dysfunctional pathways, including inhibition of inflammatory mediators, improvement of renal hemodynamics by amplifying vasodilator mechanisms and blocking vasoconstrictor mechanisms, and administration of growth factors to accelerate renal recovery, have yielded disappointing results in clinical trials.
  • Interruption of leukocyte recruitment is a potential promising approach in the treatment of septic acute renal failure, but no data in humans are presently available.
  • Activated protein C and steroid replacement therapy have been shown to reduce mortality in patients with sepsis and are now accepted adjunctive treatment options for sepsis in general.
  • [MeSH-major] Acute Kidney Injury / drug therapy. Acute Kidney Injury / etiology. Sepsis / complications
  • [MeSH-minor] Anticoagulants / agonists. Anticoagulants / therapeutic use. Antineoplastic Agents / antagonists & inhibitors. Antithrombins / therapeutic use. Endothelins / antagonists & inhibitors. Growth Substances / therapeutic use. Humans. Interleukin-8 / therapeutic use. Lipoproteins / therapeutic use. Natriuretic Peptides / therapeutic use. Nitric Oxide Synthase / antagonists & inhibitors. Platelet Activating Factor / antagonists & inhibitors. Protein C / therapeutic use. Steroids / therapeutic use. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14639066.001).
  • [ISSN] 1070-5295
  • [Journal-full-title] Current opinion in critical care
  • [ISO-abbreviation] Curr Opin Crit Care
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antineoplastic Agents; 0 / Antithrombins; 0 / Endothelins; 0 / Growth Substances; 0 / Interleukin-8; 0 / Lipoproteins; 0 / Natriuretic Peptides; 0 / Platelet Activating Factor; 0 / Protein C; 0 / Steroids; 0 / Tumor Necrosis Factor-alpha; 0 / lipoprotein-associated coagulation inhibitor; EC 1.14.13.39 / Nitric Oxide Synthase
  • [Number-of-references] 78
  •  go-up   go-down


19. Oh HY, Kwon SM, Kim SI, Jae YW, Hong SJ: Antiangiogenic effect of ZD1839 against murine renal cell carcinoma (RENCA) in an orthotopic mouse model. Urol Int; 2005;75(2):159-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiangiogenic effect of ZD1839 against murine renal cell carcinoma (RENCA) in an orthotopic mouse model.
  • We evaluated the antitumor and antiangiogenesis activities of ZD1839 in a murine renal cell carcinoma (RENCA) model.
  • For the in vivo studies, RENCA cells were adsorbed in Gelfoam and implanted into BALB/cJ mouse parenchyma with an agarose bar.
  • Western blot analysis was performed to observe EGFR expression in RENCA cells and tumor tissues.
  • ZD1839 treatment resulted in a marked decrease in tumor growth compared with saline treatment.
  • Genistein also suppressed tumor growth and decreased MVD and VEGF level, but the efficacies were less than with ZD1839.
  • CONCLUSION: The suppressive activity of ZD1839 on RENCA tumor growth was accompanied by decreases in the MVD and VEGF production.
  • These results suggest that the antitumor effect of ZD1839 in a RENCA model is mediated partially by the inhibition of tumor angiogenesis.
  • [MeSH-major] Neovascularization, Pathologic / prevention & control. Quinazolines / pharmacology. Receptor, Epidermal Growth Factor / analysis. Tumor Cells, Cultured / drug effects
  • [MeSH-minor] Animals. Biopsy, Needle. Blotting, Western. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / pathology. Cell Proliferation / drug effects. Disease Models, Animal. Enzyme-Linked Immunosorbent Assay. Female. Immunohistochemistry. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Mice. Mice, Inbred BALB C. Sensitivity and Specificity. Transplantation, Heterologous

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16123571.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


20. Munakata S, Tahara H, Kojima K, Kishimoto T: Micropapillary urothelial carcinoma of the renal pelvis: report of a case and review of the literature. Med Sci Monit; 2007 Apr;13(4):CS47-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micropapillary urothelial carcinoma of the renal pelvis: report of a case and review of the literature.
  • We report a rare case of MPUC of the renal pelvis.
  • She had a mass in the left renal pelvis with massive infiltration in the renal parenchyma.
  • Although she received chemotherapy, she died of disease 14 months after operation.
  • Histologically, MPUC was found in 40% of the tumor, mostly in the infiltrating portion.
  • CONCLUSIONS: Here we present a rare case of MPUC arising in the renal pelvis with thorough review of the literature.
  • [MeSH-major] Carcinoma, Papillary / pathology. Kidney Neoplasms / pathology. Ureteral Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392655.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 30
  •  go-up   go-down


21. Kitasato A, Tajima Y, Kuroki T, Tsutsumi R, Tsuneoka N, Adachi T, Mishima T, Kanematsu T: Limited pancreatectomy for metastatic pancreatic tumors from renal cell carcinoma. Hepatogastroenterology; 2010 Mar-Apr;57(98):354-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited pancreatectomy for metastatic pancreatic tumors from renal cell carcinoma.
  • BACKGROUND/AIMS: Metastasis of renal cell carcinoma (RCC) to distant organs occurs commonly, even after radical nephrectomy, but metastatic lesions are rarely detected in the pancreas.
  • METHODOLOGY: Since therapeutic modalities including chemotherapy or radiation are ineffective for metastatic tumors, surgical intervention is a treatment of choice in selected patients.
  • RESULTS: We used limited resection of the pancreas combined with removal of the uncinate process and distal pancreatectomy for a 65-year-old woman with multifocal pancreatic metastases located in the uncinate process, body, and tail of the pancreas, which were detected 6 years after radical nephrectomy for RCC.
  • This surgical procedure allowed preservation of about 40% of the pancreatic parenchyma, with complete excision of metastatic tumors in the pancreas.
  • CONCLUSIONS: The patient has had an excellent quality of life with well-preserved pancreatic function and no evidence of tumor recurrence for 31 months after pancreatic surgery.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / pathology. Pancreatectomy / methods. Pancreatic Neoplasms / secondary. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Staging. Nephrectomy. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583442.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


22. Sarhan OM, El-Baz M, Sarhan MM, Ghali AM, Ghoneim MA: Bilateral Wilms' tumors: single-center experience with 22 cases and literature review. Urology; 2010 Oct;76(4):946-51
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Bilateral Wilms' tumors represent a therapeutic challenge.
  • The primary aim of management is eradication of the neoplasm and preservation of renal function.
  • Of the 22 patients, 6 underwent initial surgical resection followed by chemotherapy and 16 underwent initial biopsy and preoperative chemotherapy.
  • The final oncologic and renal outcomes were assessed.
  • The survival for the initial chemotherapy and initial surgery groups was essentially similar.
  • The median volume of preserved renal parenchyma was 40%.
  • All patients had good renal function during follow-up, except for 1 patient who had undergone bilateral nephrectomy.
  • CONCLUSIONS: Bilateral Wilms' tumors impose 2 conflicting issues: elimination of the pathology and preservation of the renal function.
  • Currently, treatment regimens involving initial chemotherapy followed by conservative surgery can achieve these goals in an important proportion of patients.
  • [MeSH-major] Kidney Neoplasms / epidemiology. Neoplasms, Multiple Primary / epidemiology. Neoplasms, Second Primary / epidemiology. Wilms Tumor / epidemiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Egypt / epidemiology. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infant. Kaplan-Meier Estimate. Male. Mesna / administration & dosage. Neoadjuvant Therapy. Nephrectomy / methods. Nephrectomy / statistics & numerical data. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20708784.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


23. Velders AH, Bergamo A, Alessio E, Zangrando E, Haasnoot JG, Casarsa C, Cocchietto M, Zorzet S, Sava G: Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine). J Med Chem; 2004 Feb 26;47(5):1110-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
  • Ruthenium compounds have gained large interest for their potential application as chemotherapeutic agents, and in particular the complexes of the type (X)[trans-RuCl4(dmso-S)L] (X = HL or Na, NAMI-A or NAMI, respectively, for L = imidazole) are under investigation for their antimetastatic properties.
  • The NAMI-A-type Ru(III) complex 1, (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)] (dmtp is 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine), and the corresponding sodium analogue 2, (Na)[trans-RuCl4(dmso-S)(dmtp)], were synthesized.
  • The molecular structures of 1 and 3 were determined by single-crystal X-ray diffraction analyses and prove the importance of the hydrogen-bonding properties of dmtp to stabilize hydrolysis products.
  • In vitro 1 (a) is not cytotoxic on tumor cells, following challenges from 1 to 72 h and concentrations up to 100 microM, (b) inhibits matrigel invasion at 0.1 mM and MMP-9 activity with an IC50 of about 1 mM, and (c) is devoid of pronounced effects on cell distribution among cell cycle phases.
  • In the lungs, 1 is significantly less concentrated than NAMI-A, whereas no differences between these two compounds were found in other organs such as tumor, liver, and kidney.
  • However, 1 caused edema and necrotic areas on liver parenchyma that are more pronounced than those caused by NAMI-A.
  • Conversely, glomerular and tubular changes on kidney are less extensive than with NAMI-A.
  • In conclusion, 1 confirms the excellent antimetastatic properties of this class of NAMI-A-type compounds and qualifies as an interesting alternative to NAMI-A for treating human cancers.
  • [MeSH-minor] Animals. Cell Cycle / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Crystallography, X-Ray. Drug Screening Assays, Antitumor. Hydrolysis. Kidney / drug effects. Kidney / pathology. Liver / drug effects. Liver / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Magnetic Resonance Spectroscopy. Mammary Neoplasms, Animal / pathology. Matrix Metalloproteinase 9 / chemistry. Mice. Molecular Structure. Neoplasm Invasiveness. Spectrophotometry, Ultraviolet. Structure-Activity Relationship. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14971891.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organometallic Compounds; 0 / aquatrichloro(dimethylsulfoxide)(5,7-(1,2,4)triazolo(1,5-a)pyrimidine)ruthenium(III); 0 / tetrachloro(dimethylsulfoxide)(5,7-dimethyl(1,2,4)triazolo(1,5-a)pyrimidine)ruthernium(III); 7UI0TKC3U5 / Ruthenium; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


24. Kim FJ, Campagna A, Khandrika L, Koul S, Byun SS, vanBokhoven A, Moore EE, Koul H: Individualized medicine for renal cell carcinoma: establishment of primary cell line culture from surgical specimens. J Endourol; 2008 Oct;22(10):2361-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Individualized medicine for renal cell carcinoma: establishment of primary cell line culture from surgical specimens.
  • BACKGROUND: The lack of effective "in vivo" and "in vitro" models to predict success of pharmacological therapy for patients with renal cell carcinoma, as well as, the variety of cancer cell types demands the development of better experimental models to understand the pathophysiology of the disease and evaluate drug sensitivity in vitro.
  • PURPOSE: To develop primary renal cancer cell culture irrespective of tumor grade and tumor type, harvested from the patient's pathological specimen immediately after the laparoscopic radical nephrectomy to study potential "in vivo" pharmacological sensitivity.
  • The mean size of the renal masses was 7.56+/-3.1 cm.
  • Normal and pathological renal tissue was collected immediately after the specimen was extracted and submitted to enzymatic digestion for 16-24 hours.
  • RESULTS: Establishment of cell line culture from all the patients' specimens irrespective of tumor grade and tumor type was achieved successfully.
  • In addition to the tumor cell line culture, normal parenchyma tissue yielded primary cell lines to allow testing the response of tumor types to various pharmacological therapeutic agents and toxicity of such treatments to healthy tissue.
  • From the initial collection of the specimens obtained after the removal of the kidney to the development of cell lines took occurred in average 32+6 hrs.
  • CONCLUSION: The development of renal cancer cell cultures in vitro is labor intense but may yield a more realistic model to tailor pharmacological therapies and predict therapeutic success prior to "in vivo" application-a step in the direction of individualized medicine for RCC.

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2008 May;179(5):2057-63 [18355855.001]
  • [Cites] Methods Mol Med. 2005;107:283-90 [15492379.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):408-11 [12853787.001]
  • [Cites] Kidney Int. 1984 Feb;25(2):383-90 [6727133.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1030:144-9 [15659791.001]
  • [Cites] Exp Cell Res. 2004 Nov 15;301(1):1-7 [15501438.001]
  • [Cites] Curr Mol Med. 2004 Dec;4(8):849-54 [15579032.001]
  • [Cites] Cell Biol Int Rep. 1988 May;12(5):355-64 [3401935.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] J Cell Physiol. 1980 Nov;105(2):369-78 [6257734.001]
  • [ErratumIn] J Endourol. 2009 Jan;23(1):181
  • (PMID = 18937598.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / P50 GM049222; United States / PHS HHS / / R01DKO54084
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2996254
  •  go-up   go-down


25. Shiga Y, Suzuki K, Tsutsumi M, Ishikawa S: Transitional cell carcinoma of the renal pelvis in a patient with cyclophosphamide therapy for malignant lymphoma: a case report and literature review. Hinyokika Kiyo; 2002 May;48(5):301-5
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the renal pelvis in a patient with cyclophosphamide therapy for malignant lymphoma: a case report and literature review.
  • A 59-year-old man, who had received cyclophosphamide therapy for malignant lymphoma, was suffering from gross hematuria and consulted our institute.
  • Computerized tomography (CT), intravenous pyelography (IVP) and retrograde pyelography (RP) revealed a left renal pelvic tumor.
  • Histopathological diagnosis of the left renal pelvic tumor was transitional cell carcinoma, invading the renal parenchyma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Carcinoma, Transitional Cell / chemically induced. Cyclophosphamide / adverse effects. Kidney Neoplasms / chemically induced. Lymphoma / drug therapy. Neoplasms, Second Primary / chemically induced
  • [MeSH-minor] Humans. Kidney Pelvis. Male. Middle Aged


26. Biyikli NK, Tuğtepe H, Sener G, Velioğlu-Oğünç A, Cetinel S, Midillioğlu S, Gedik N, Yeğen BC: Oxytocin alleviates oxidative renal injury in pyelonephritic rats via a neutrophil-dependent mechanism. Peptides; 2006 Sep;27(9):2249-57
Hazardous Substances Data Bank. UREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxytocin alleviates oxidative renal injury in pyelonephritic rats via a neutrophil-dependent mechanism.
  • BACKGROUND: Urinary tract infection (UTI) may cause inflammation of the renal parenchyma and may lead to impairment in renal function and scar formation.
  • We investigated the possible therapeutic effects of OT against Escherichia coli induced pyelonephritis in rats both in the acute and chronic setting.
  • METHODS: Twenty-four Wistar rats were injected 0.1 ml solution containing E. coli ATCC 25922 10(10) colony forming units/ml into left renal medullae.
  • Renal function tests (urea, creatinine), systemic inflammation markers [lactate dehydrogenase (LDH) and tumor necrosis factor alpha (TNF-alpha)] and renal tissue malondialdehyde (MDA) as an end product of lipid peroxidation, glutathione (GSH) as an antioxidant parameter and myeloperoxidase (MPO) as an indirect index of neutrophil infiltration were studied.
  • RESULTS: Blood urea, creatinine, and TNF-alpha levels were increased, renal tissue MDA and MPO levels were elevated and GSH levels were decreased in both of the pyelonephritic (acute and chronic) rats.
  • All of these parameters and elevation of LDH at the late phase were all reversed to normal levels by OT treatment.
  • CONCLUSION: OT alleviates oxidant renal injury in pyelonephritic rats by its anti-oxidant actions and by preventing free radical damaging cascades that involves excessive infiltration of neutrophils.
  • [MeSH-major] Antioxidants / therapeutic use. Kidney / drug effects. Neutrophils / drug effects. Oxidative Stress. Oxytocin / therapeutic use. Pyelonephritis / drug therapy
  • [MeSH-minor] Animals. Collagen / metabolism. Creatinine / blood. Creatinine / metabolism. Glutathione / metabolism. Kidney Function Tests. L-Lactate Dehydrogenase / blood. L-Lactate Dehydrogenase / metabolism. Male. Malondialdehyde / metabolism. Rats. Rats, Wistar. Tumor Necrosis Factor-alpha. Urea / blood. Urea / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. Oxytocin .
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707192.001).
  • [ISSN] 0196-9781
  • [Journal-full-title] Peptides
  • [ISO-abbreviation] Peptides
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Tumor Necrosis Factor-alpha; 4Y8F71G49Q / Malondialdehyde; 50-56-6 / Oxytocin; 8W8T17847W / Urea; 9007-34-5 / Collagen; AYI8EX34EU / Creatinine; EC 1.1.1.27 / L-Lactate Dehydrogenase; GAN16C9B8O / Glutathione
  •  go-up   go-down


27. Ahmed MM, Mubashir E, Dossabhoy NR: Isolated renal sarcoidosis: a rare presentation of a rare disease treated with infliximab. Clin Rheumatol; 2007 Aug;26(8):1346-9
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated renal sarcoidosis: a rare presentation of a rare disease treated with infliximab.
  • Acute renal failure (ARF) as an isolated manifestation of sarcoidosis is rare.
  • We describe a case of sarcoidosis presenting as transient polyarthritis and ARF due to isolated granulomatous infiltration of the renal parenchyma.
  • Renal biopsy showed granulomatous interstitial nephritis with noncaseating granulomas consistent with sarcoidosis.
  • Prednisone of 60 mg daily resulted in significant improvement in renal function.
  • Because of recurrent flares on steroid taper and steroid toxicity, treatment with infliximab, an anti-tumor necrosis factor-alpha (TNF-alpha) antibody, was instituted and resulted in stabilization of renal function despite steroid taper.
  • Although uncommon, renal sarcoidosis should be considered in the differential diagnosis of acute or chronic renal failure of uncertain etiology, as early diagnosis and treatment can lead to recovery of renal function and prevent interstitial fibrosis.
  • Corticosteroids are mainstay of therapy.
  • [MeSH-major] Acute Kidney Injury / drug therapy. Antibodies, Monoclonal / therapeutic use. Antirheumatic Agents / therapeutic use. Sarcoidosis / drug therapy

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2002 May 1;168(9):4620-7 [11971010.001]
  • [Cites] Am J Nephrol. 1989;9(1):51-5 [2719063.001]
  • [Cites] Am J Clin Pathol. 1949 Aug;19(8):725-49 [18135500.001]
  • [Cites] Arthritis Rheum. 2005 Oct 15;53(5):788-91 [16208666.001]
  • [Cites] N Engl J Med. 1955 Jan 13;252(2):44-9 [13223979.001]
  • [Cites] Nephron. 1984;37(4):246-9 [6462314.001]
  • [Cites] Medicine (Baltimore). 1999 Mar;78(2):65-111 [10195091.001]
  • [Cites] Medicine (Baltimore). 1952 Feb;31(1):1-132 [14899212.001]
  • [Cites] Postgrad Med J. 1970 Aug;46(538):526-9 [5481106.001]
  • [Cites] Ann Med Interne (Paris). 2001 Feb;152(1):45-50 [11240426.001]
  • [Cites] Can Med Assoc J. 1979 Nov 17;121(10):1367-71 [519562.001]
  • (PMID = 16850114.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antirheumatic Agents; B72HH48FLU / Infliximab
  •  go-up   go-down






Advertisement